New Release: Alpha testing version has been released.

Aminolevulinic Acid

L01X - Other antineoplastic agents ATC L01XD04 Small molecule approved 1999 Oral Topical Prodrug Natural product

Active form: Protoporphyrin.

JFDA label: Gliolan powder for oral solution

Mechanism of Action

12.1 Mechanism of Action ALA occurs endogenously as a metabolite that is formed in the mitochondria from succinyl-CoA and glycine. Exogenous administration of ALA leads to accumulation of the ALA metabolite PpIX in tumor cells. The reason for the accumulation of PpIX in neoplastic brain tissue is not known. During glioma surgery, Gleolan is used with an operating microscope adapted with a blue emitting light source (power density 40-80 mW/cm 2 ) and filters for excitation light of wavelength 375 to 440 nm, and observation at wavelengths of 620 to 710 nm. This allows tumor tissue to be visualized as red fluorescence. Tissue lacking sufficient PpIX concentrations appears blue.

Indications

Approved

  • Neoplasms — neoplasm

Off-label

  • Basal Cell Nevus Syndrome
  • Brain Neoplasms
  • Carcinoma, Basal Cell
  • Desmoid Tumors
  • Glioblastoma
  • Infections
  • Keratosis, Actinic
  • Neurofibromatosis 1
  • Paraganglioma

Contraindications

Source: openFDA

  • Hypersensitivity to the aminolevulinic acid (ALA) or porphyrins. [see Warnings and Precautions (5.3) ] Acute or chronic types of porphyria, due to potential ineffectiveness of the drug in these patients. Hypersensitivity to aminolevulinic acid (ALA) or porphyrins. ( 4 , 5.3 , 6.2 ) Acute or chronic types of porphyria. ( 4 ) Absolute

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Vascular disorders (1)

Common Haemorrhage

Hepatobiliary disorders (3)

Very Common Alanine aminotransferase increased · Aspartate aminotransferase increased · Blood bilirubin increased

Blood and lymphatic system disorders (1)

Common Haemoglobin

Skin and subcutaneous tissue disorders (5)

Very Common Pruritus · Skin disorder · Skin hyperpigmentation

Common Rash pustular · Urticaria

Investigations (2)

Very Common Amylase increased · Gamma-glutamyltransferase increased

General disorders and administration site conditions (7)

Very Common Scab

Common Dysaesthesia · Excoriation · Oedema · Pain · Tenderness · Ulcer

Dosing

Source: openFDA

For oral use only ( 2.1 ) Recommended reconstituted oral dose of Gleolan is 20 mg/kg. ( 2.1 ) Administer Gleolan to patient orally 3 hours (range 2 to 4 hours) before anesthesia. ( 2.1 ) See Full Prescribing Information for reconstitution information. ( 2.2 ) Use appropriate visualization techniques with appropriate surgical microscopes and light source filters. ( 2.4 ) 2.1 Recommended Dose For oral use only The recommended oral dose of reconstituted Gleolan is 20 mg / kg body weight. More than 1 vial may be required. 2.2 Reconstitution of Gleolan Gleolan powder must be reconstituted prior to administration by a healthcare provider according to the following instructions: Determine the total number of vials needed to achieve the intended dose for the patient according to the equation below (rounded up to the nearest whole vial): # of vials = Patient Body Weight (kg) 75 kg / vial Completely remove the white cap and aluminum crimp seal from each vial. Remove and retain the rubber stopper from the vial. Using an appropriate volumetric measuring device (e.g., flask, graduated cylinder, dosing syringe), measure 50 mL of drinking water and add to each vial containing 1,500 mg of Gleolan. Gently swirl the vial to completely dissolve the powder. The resulting reconstituted solution (30 mg of Gleolan per mL) is clear and colorless to slightly yellowish. If required, replace the stopper and store reconstituted solution for up to 24 hours at room temperature prior to administration. 2.3 Gleolan Administration Gleolan is for ORAL USE ONLY. The reconstituted Gleolan solution is administered according to the following steps: Calculate the administration volume, in mL, to achieve the intended dose according to the following equation: Administration Volume (mL) = Patient Body Weight (kg) * 20 mg/kg 30 mg/mL Transfer the entire contents of the prepared vial(s) into an appropriate dosing container (e.g., oral medicine bottle); ensure the entire contents of the vials are transferred. After transfer, discard the empty vial(s). Using a disposable volumetric syringe, remove the administration volume of reconstituted Gleolan solution from the dosing container and transfer to a separate oral dosing container. Discard unneeded volume of Gleolan solution. Administer orally 3 hours (range 2 to 4 hours) prior to induction of anesthesia. 2.4 Imaging Instructions Gleolan should be used with a standard surgical operating microscope adapted with a blue light emitting light source (power density 40-80 mW/cm 2 ) and ancillary excitation and emission filters to visualize fluorescence excitation in the wavelength of 375 to 440 nm and for observation from 620 to 710 nm. Filters transmit porphyrin fluorescence as red-violet, as well as a fraction of backscattered blue excitation light necessary for distinguishing nonfluorescing tissue. Gleolan should only be used by neurosurgeons who have completed a training program on use of fluorescence in surgery. Training is provided by the distributor.

Warnings & Precautions

Source: openFDA

Warnings & Precautions

Phototoxic reactions: Do not administer phototoxic drugs (St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines), and topical preparations containing ALA for 24 hours during the perioperative period. Reduce exposure to sunlight or room lights for 48 hours after oral administration of Gleolan. ( 5.1 , 7 ) Risk of misinterpretation: Non-fluorescing tissue in the surgical field does not rule out the presence of tumor. ( 5.2 , 14 )

Risk of Phototoxic Reaction Due to the risk of phototoxic reactions, d

Risk of Phototoxic Reaction Due to the risk of phototoxic reactions, do not administer phototoxic drugs (St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines), and topical preparations containing ALA for 24 hours during the perioperative period [see Drug Interactions (7) ] . Reduce exposure to sunlight or room lights for 48 hours after administration of Gleolan.

Risk of Misinterpretation Errors may occur with the use of Gleolan for

Risk of Misinterpretation Errors may occur with the use of Gleolan for intraoperative visualization of malignant glioma, including false negatives and false positives. Non-fluorescing tissue in the surgical field does not rule out the presence of tumor in patients with glioma [see Clinical Studies (14) ] . Fluorescence may be seen in areas of inflammation or metastases from other tumor types.

Hypersensitivity Reactions Hypersensitivity reactions, including serio

Hypersensitivity Reactions Hypersensitivity reactions, including serious hypersensitivity reactions have occurred; these reactions include anaphylactic shock, swelling, and urticaria [see Contraindications (4) , Adverse Reactions (6.2) ] . Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions.

Pregnancy & Lactation

Pregnancy

Lactation

No Data Hale L3

This treatment appeared to preserve nipple anatomy for breastfeeding.[ 1 - 3 ]

Chemistry & Properties

2D structure
FormulaC5H9NO3
Molecular weight131.13 g/mol
IUPAC name5-amino-4-oxopentanoic acid
CAS106-60-5
PubChem CID137
InChIKeyZGXJTSGNIOSYLO-UHFFFAOYSA-N
logP-0.62 (XLogP -3.8)
Polar surface area80.39 Ų
H-bond acceptors / donors3 / 2
Drug-likeness (QED)0.53
Lipinski violations0
SMILESNCC(=O)CCC(=O)O

Biology & Pharmacokinetics

Pharmacokinetics predicted

Bioavailability10.0%
Half-life1.758 h
Volume of distribution0.248 L/kg
Protein binding7.3%
BBB penetrantNo

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)PEPT1 (Inhibitor)BCRP (Substrate)MDR1 (Substrate)P-gp (Substrate)PEPT1 (Substrate)PEPT2 (Substrate)

Drug–drug interactions (94, DDInter)

Interacting drugSeverityManagement
Acetazolamide major
Acitretin major
Adapalene (topical) major
Afatinib major
Alectinib major
Alitretinoin (topical) major
Amiodarone major
Avapritinib major
Bendroflumethiazide major
Bexarotene major
Bexarotene (topical) major
Bicalutamide major
Bumetanide major
Capmatinib major
Celecoxib major
Cetuximab major
Chlorothiazide major
Chlorpromazine major
Chlorpropamide major
Chlorthalidone major
Ciprofloxacin major
Cobimetinib major
Dabrafenib major
Dapsone major
Demeclocycline major
Doxycycline major
Eravacycline major
Erlotinib major
Etacrynic acid major
Fenoprofen major
Fluphenazine major
Flurbiprofen major
Furosemide major
Gatifloxacin major
Gefitinib major
Gemifloxacin major
Glimepiride major
Glipizide major
Glyburide major
Griseofulvin major

Showing 40 of 94.

Registered Products (1)

BrandForm / strengthPackAgentCitizen (JOD)
Gliolan powder for oral solution Solution 30 mg/1 ml 30 mg Al Hilal Drug Store